Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial

Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations including exon 20 insertions (EGFRex20ins) in non–small cell lung cancer, was evaluated in a phase 1/2 dose-escalation/expansion trial (ClinicalTrials.gov NCT02716116). Dose escalation identified 16...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Discov
Main Authors: Riely, Gregory J., Neal, Joel W., Camidge, D. Ross, Spira, Alexander I., Piotrowska, Zofia, Costa, Daniel B., Tsao, Anne S., Patel, Jyoti D., Gadgeel, Shirish M., Bazhenova, Lyudmila, Zhu, Viola W., West, Howard L., Mekhail, Tarek, Gentzler, Ryan D., Nguyen, Danny, Vincent, Sylvie, Zhang, Steven, Lin, Jianchang, Bunn, Veronica, Jin, Shu, Li, Shuanglian, Jänne, Pasi A.
Format: Artigo
Sprog:Inglês
Udgivet: 2021
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8295177/
https://ncbi.nlm.nih.gov/pubmed/33632775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1598
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker